Related Experiment Video

Updated: May 29, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Gefitinib for non-small-cell lung cancer treatment

Armida D'Incecco1, Federico Cappuzzo

  • 1Medical Oncology Department, Istituto Toscano Tumori-Ospedale Civile, Italy.

Expert Opinion on Drug Safety
|September 13, 2011
PubMed
Abstract

Insights

Gefitinib, an EGFR tyrosine kinase inhibitor, is a highly effective first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. It offers superior outcomes and a better safety profile compared to chemotherapy, especially for elderly patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Gefitinib is an effective EGFR tyrosine kinase inhibitor (EGFR-TKI) for advanced non-small cell lung cancer (NSCLC).
  • EGFR-TKIs show superiority over chemotherapy in first-line treatment for patients with EGFR mutations, improving response rates, progression-free survival, and quality of life.

Purpose of the Study:

  • To review the efficacy and safety of gefitinib in advanced NSCLC.
  • To summarize clinical trial data on gefitinib for NSCLC treatment.

Main Methods:

  • Analysis of published gefitinib data in lung cancer using PubMed.
  • Review of major clinical trials involving gefitinib in advanced NSCLC patients.

Main Results:

  • Gefitinib demonstrates superior efficacy in patients with activating EGFR mutations compared to chemotherapy.
  • Improved response rate, progression-free survival, toxicity profile, and quality of life observed with gefitinib.
  • Molecular characterization is essential for selecting optimal treatment.

Conclusions:

  • EGFR-TKIs, including gefitinib, represent the optimal treatment for patients with EGFR mutations in advanced NSCLC.
  • Gefitinib is well-tolerated and suitable for special populations like elderly patients and those with poor performance status.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...